Skip to content
OpenCapital
Get started

Biohaven BHVN Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value at other companies

ADMA Biologics logo
ADMA BiologicsADMA
——
Immunovant, Inc. logo
Immunovant, Inc.IMVT
——

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value?
Biohaven (BHVN) reported share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value of $10.9M in Q1 2026.
How has Biohaven's share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value changed year-over-year?
Biohaven's share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value decreased by 89.0% year-over-year, from $99.1M to $10.9M.